Velocity Skierniewice Sp. z o.o. — Clinical Trial Site

44 Registered trials

14 Currently recruiting

Organisation

Velocity Skierniewice Sp. z o.o.

Location

Skierniewice, Poland

Identifier

ORG-100040849

Address

Ul. Peowiakow 1, 22-400, Poland

Departments

.
2707 : NA
4803: Pulmonology
5214: Pulmonology
8534:Cardiology
Allergology
Cardiology
cardiology department
Clinmedica Research
Clinmedica Research Sp. z o.o.
N/A
NA
Not Applicable
Physician
Pneumology
Private Practice
Velocity Skierniewice
Velocity Skierniewice Sp. z o.o.

Clinical trials at this site (44)

Search interface

Randomised efficacy and safety clinical trial of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by … Pending

2023-507427-28-00 seasonal allergic rhinitis and/or rhinoconjunctivitis 5
A study to evaluate the efficacy, immunogenicity, and safety of an RSV and hMPV VLP vaccine compared with placebo in participants aged 60 ye… Pending

2024-513740-28-00 Respiratory Syncytial Virus and Human Metapneumovirus 5
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D… Recruiting

2025-523123-22-00 Chronic Kidney Disease 5 2026-05-07
Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting

2025-521456-35-00 Mild to moderate asthma 4 2026-04-13
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting

2025-522403-17-00 Nummular Dermatitis 5 2026-04-10
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia Recruiting

2024-516411-24-00 Insomnia Disorder 5 2026-02-25
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A Study to Assess the Efficacy, Safety, and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Co… Recruiting

2025-520690-39-00 Moderately to Severely Active Ulcerative Colitis (UC) 4 2025-11-04
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis Recruiting

2023-508817-18-00 Perennial Allergic Rhinitis (PAR) 5 2024-10-08
Long-term clinical trial of PQ Grass in paediatric subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass poll… Recruiting

2023-508520-36-00 Seasonal allergic rhinitis/rhinoconjunctivitis induced 5 2024-09-06
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerabilit… Recruiting

2023-504835-42-00 Heart Failure (Heart Failure with Reduced Ejection Frac 4 2024-02-29
Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended

2025-520488-42-00 Moderate-to-Severe Chronic Obstructive Pulmonary Diseas 4 2025-09-17
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Ended

2024-510753-10-00 Prurigo Nodularis 5 2024-11-01
A clinical study investigating OM-85 efficacy and safety in children suffering from Recurrent Wheezing Ended

2024-511083-90-00 Recurrent wheezing 4 2024-10-03
MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hyper… Ended

2023-508670-28-00 Hypertension 5 2024-08-26
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended

2023-505435-12-00 Asthma 5 2024-06-04
Selective Treatment of Oral Povorcitinib in Vitiligo Study 2 (STOP-V2) Ended

2023-506011-18-00 Vitiligo 5 2024-04-17
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08